Retraction notice to “Polysaccharide from Angelica sinensis ameliorates high-fat diet and STZ-induced hepatic oxidative stress and inflammation in diabetic mice by activating Sirt1-AMPK pathway” (JNB (2017) 43 (88–97) (S0955286316302716) (10.1016/j.jnutbio.2017.02.001));Polysaccharide from Angelica sinensis ameliorates high-fat diet and STZ-induced hepatic oxidative stress and inflammation in diabetic mice by activating the Sirt1–AMPK pathway

Journal of Nutritional Biochemistry

Volumn 43, Issue , 2017, Pages 88-97

  Wang, Kaiping ^a   Tang, Zhuohong ^a   Wang, Jinglin ^b   Cao, Peng ^a   Li, Qiang ^b   Shui, Weizhi ^a   Wang, Hongjing ^a   Zheng, Ziming ^b   Zhang, Yu ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNION HOSPITAL   (China)

Author keywords

Inflammation; Liver injury; Oxidative stress; Polysaccharide from Angelica sinensis; Sirt1 AMPK signaling pathway; Type 2 diabetes

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CELL PROTEIN; CHOLESTEROL; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE 2; LIVER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; POLYSACCHARIDE; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGELICA SINENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ISOLATION; DRUG PURIFICATION; DRUG SYNTHESIS; DYSLIPIDEMIA; ENZYME ACTIVITY; EXPERIMENTAL HEPATITIS; GEL PERMEATION CHROMATOGRAPHY; GENE REPRESSION; GLUCOSE BLOOD LEVEL; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIVER INJURY; LIVER PROTECTION; LIVER TISSUE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; RETRACTION NOTICE;

EID: 85014319177     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.07.007     Document Type: Erratum

References (46)

1. [1] Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94 (2011), 311–321.
2. [2] Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
3. [3] Oggioni, C., Lara, J., Wells, J.C., Soroka, K., Siervo, M., Shifts in population dietary patterns and physical inactivity as determinants of global trends in the prevalence of diabetes: an ecological analysis. Nutr Metab Cardiovasc Dis 24 (2014), 1105–1111.
4. [4] Saravanan, S., Pari, L., Role of thymol on hyperglycemia and hyperlipidemia in high fat diet-induced type 2 diabetic C57BL/6 J mice. Eur J Pharmacol 761 (2015), 279–287.
5. [5] Subhasree, N., Kamella, A., Kaliappan, I., Agrawal, A., Dubey, G.P., Antidiabetic and antihyperlipidemic activities of a novel polyherbal formulation in high fat diet/streptozotocin induced diabetic rat model. Indian J Pharmacol 47 (2015), 509–513.
6. [6] Skovso, S., Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig 5 (2014), 349–358.
7. [7] Davidson, E.P., Holmes, A., Coppey, L.J., Yorek, M.A., Effect of combination therapy consisting of enalapril, alpha-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat. Eur J Pharmacol 765 (2015), 258–267.
8. [8] Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.C., Roudot-Thoraval, F., The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58 (2013), 593–608.
9. [9] Caldwell, S.H., Oelsner, D.H., Iezzoni, J.C., Hespenheide, E.E., Battle, E.H., Driscoll, C.J., Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 (1999), 664–669.
10. [10] Suman, R.K., Ray Mohanty, I., Borde, M.K., Maheshwari, U., Deshmukh, Y.A., Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Adv Pharmacol Sci, 2016, 2016, 9463476.
11. [11] Nagaishi, K., Ataka, K., Echizen, E., Arimura, Y., Fujimiya, M., Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. Hepatology 59 (2014), 1816–1829.
12. [12] Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52 (2012), 59–69.
13. [13] Chitturi, S., Farrell, G.C., Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21 (2001), 27–41.
14. [14] Yu, J.W., Sun, L.J., Liu, W., Zhao, Y.H., Kang, P., Yan, B.Z., Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the Sirt1–AMPK signaling pathway. Int J Infect Dis 17 (2013), e539–e545.
15. [15] Gruzman, A., Babai, G., Sasson, S., Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 6 (2009), 13–36.
16. [16] Hardie, D.G., AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007), 774–785.
17. [17] Han, J.Y., Lee, S., Yang, J.H., Kim, S., Sim, J., Kim, M.G., et al. Korean Red Ginseng attenuates ethanol-induced steatosis and oxidative stress via AMPK/Sirt1 activation. J Ginseng Res 39 (2015), 105–115.
18. [18] Jung, T.W., Hwang, H.J., Hong, H.C., Yoo, H.J., Baik, S.H., Choi, K.M., BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK–PPARdelta-dependent pathway in mice. Diabetologia 58:9 (2015), 2096–2105.
19. [19] Salminen, A., Hyttinen, J.M., Kaarniranta, K., AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med 89 (2011), 667–676.
20. [20] Gao, J., Han, Y.L., Jin, Z.Y., Xu, X.M., Zha, X.Q., Chen, H.Q., et al. Protective effect of polysaccharides from Opuntia dillenii Haw fruits on streptozotocin-induced diabetic rats. Carbohydr Polym 124 (2015), 25–34.
21. [21] Zhou, J., Xu, G., Yan, J., Li, K., Bai, Z., Cheng, W., et al. Rehmannia glutinosa (Gaertn.) DC. Polysaccharide ameliorates hyperglycemia, hyperlipemia and vascular inflammation in streptozotocin-induced diabetic mice. J Ethnopharmacol 164 (2015), 229–238.
22. [22] Zhou, J., Yan, J., Bai, Z., Li, K., Huang, K., Hypoglycemic activity and potential mechanism of a polysaccharide from the loach in streptozotocin-induced diabetic mice. Carbohydr Polym 121 (2015), 199–206.
23. [23] Cao, W., Li, X.Q., Wang, X., Fan, H.T., Zhang, X.N., Hou, Y., et al. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway. Phytomedicine 17 (2010), 598–605.
24. [24] Yu, F., Li, H., Meng, Y., Yang, D., Extraction optimization of Angelica sinensis polysaccharides and its antioxidant activity in vivo. Carbohydr Polym 94 (2013), 114–119.
25. [25] Wang, K., Cao, P., Wang, H., Tang, Z., Wang, N., Wang, J., et al. Chronic administration of Angelica sinensis polysaccharide effectively improves fatty liver and glucose homeostasis in high-fat diet-fed mice. Sci Rep, 6, 2016, 26229.
26. [26] Wang, K., Song, Z., Wang, H., Li, Q., Cui, Z., Zhang, Y., Angelica sinensis polysaccharide attenuates concanavalin A-induced liver injury in mice. Int Immunopharmacol 31 (2016), 140–148.
27. [27] Zhang, Y., Cheng, Y., Wang, N., Zhang, Q., Wang, K., The action of JAK, SMAD and ERK signal pathways on hepcidin suppression by polysaccharides from Angelica sinensis in rats with iron deficiency anemia. Food Funct 5 (2014), 1381–1388.
28. [28] McGrath, J.C., McLachlan, E.M., Zeller, R., Transparency in research involving animals: the Basel Declaration and new principles for reporting research in BJP manuscripts. Br J Pharmacol 172 (2015), 2427–2432.
29. [29] Wang, K., Cao, P., Shui, W., Yang, Q., Tang, Z., Zhang, Y., Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. Food Funct 6 (2015), 902–909.
30. [30] Liang, C., Curry, B.J., Brown, P.L., Zemel, M.B., Leucine modulates mitochondrial biogenesis and Sirt1–AMPK signaling in C2C12 myotubes. J Nutr Metab, 2014, 2014, 239750.
31. [31] Ford, J., Jiang, M., Milner, J., Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65 (2005), 10457–10463.
32. [32] Guo, C., Liang, T., He, Q., Wei, P., Zheng, N., Xu, L., Renoprotective effect of ramulus mori polysaccharides on renal injury in STZ-diabetic mice. Int J Biol Macromol 62 (2013), 720–725.
33. [33] He, G., Karin, M., NF-kappaB and STAT3 — key players in liver inflammation and cancer. Cell Res 21 (2011), 159–168.
34. [34] Majumdar, S.K., Inzucchi, S.E., Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?. Endocrine 44 (2013), 47–58.
35. [35] Dong, Y., Huang, J., Lin, X., Zhang, S., Jiao, Y., Liang, T., et al. Hepatoprotective effects of Yulangsan polysaccharide against isoniazid and rifampicin-induced liver injury in mice. J Ethnopharmacol 152 (2014), 201–206.
36. [36] Xu, M.Y., Hu, J.J., Shen, J., Wang, M.L., Zhang, Q.Q., Qu, Y., et al. Stat3 signaling activation crosslinking of TGF-beta1 in hepatic stellate cell exacerbates liver injury and fibrosis. Biochim Biophys Acta 2014 (1842), 2237–2245.
37. [37] Pu, X., Fan, W., Yu, S., Li, Y., Ma, X., Liu, L., et al. Polysaccharides from Angelica and Astragalus exert hepatoprotective effects against carbon-tetrachloride-induced intoxication in mice. Can J Physiol Pharmacol 93 (2015), 39–43.
38. [38] Liu, G., Liu, X., Zhang, Y., Zhang, F., Wei, T., Yang, M., et al. Hepatoprotective effects of polysaccharides extracted from Zizyphus jujube cv. Huanghetanzao. Int J Biol Macromol 76 (2015), 169–175.
39. [39] Choi, Y., Yanagawa, Y., Kim, S., Park, T., Involvement of Sirt1–AMPK signaling in the protective action of indole-3-carbinol against hepatic steatosis in mice fed a high-fat diet. J Nutr Biochem 24 (2013), 1393–1400.
40. [40] Kahn, S.E., Hull, R.L., Utzschneider, K.M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006), 840–846.
41. [41] Ren, Z., Cui, J., Huo, Z., Xue, J., Cui, H., Luo, B., et al. Cordycepin suppresses TNF-alpha-induced NF-kappaB activation by reducing p65 transcriptional activity, inhibiting IkappaBalpha phosphorylation, and blocking IKKgamma ubiquitination. Int Immunopharmacol 14 (2012), 698–703.
42. [42] Song, C.Y., Shi, J., Zeng, X., Zhang, Y., Xie, W.F., Chen, Y.X., Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway. Toxicol In Vitro 27 (2013), 1065–1071.
43. [43] Caldwell, S.H., Chang, C.Y., Nakamoto, R.K., Krugner-Higby, L., Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004), 595–617 [x].
44. [44] Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002), 1288–1295.
45. [45] Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9 (2009), 327–338.
46. [46] Yang, Z., Kahn, B.B., Shi, H., Xue, B.Z., Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 285 (2010), 19051–19059.